Morgan Stanley lowered the firm’s price target on Neurocrine (NBIX) to $173 from $175 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Reaffirming Buy: Solid Core Franchise Execution and Underappreciated Pipeline Upside Support Mid-$150s Valuation
- Neurocrine Biosciences: Durable Ingrezza Franchise and Emerging Crenessity Uptake Support Buy Rating and $190 Price Target
- Neurocrine price target raised to $204 from $203 at Citi
- Neurocrine price target lowered to $192 from $198 at H.C. Wainwright
- Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures